| Literature DB >> 23638752 |
Masaki Ikeda1, Kimie Yonemura, Satoko Kakuda, Yuichi Tashiro, Yukio Fujita, Eriko Takai, Yukiko Hashimoto, Kouki Makioka, Natsumi Furuta, Koichi Ishiguro, Risa Maruki, Jun'ichi Yoshida, Osamu Miyaguchi, Tamao Tsukie, Ryouzou Kuwano, Tsuneo Yamazaki, Haruyasu Yamaguchi, Masakuni Amari, Masamitsu Takatama, Yasuo Harigaya, Koichi Okamoto.
Abstract
We studied seven cases of Alzheimer's disease (AD). Six of the patients had presenilin 1 (PS1) mutations (PS1AD). Three novel PS1 mutations (T99A, H131R and L219R) and three other missense mutations (M233L, H163R and V272A) were found in the PS1AD group. We measured the levels of phosphorylated tau (ptau-181, ptau-199) and Aβ (Aβ1-42, Aβ1-40 and Aβ1-38) in the cerebrospinal fluid (CSF) of PS1AD patients, early-onset sporadic AD (EOSAD), late-onset sporadic AD (LOSAD) and non-demented subjects (ND). The CSF levels of Aβ1-42 in the three AD groups were significantly lower than those of the ND group (p < 0.0001). CSF levels of Aβ1-42 in the PS1AD group were significantly lower than those in the two sporadic AD groups. The Aβ1-40 and Aβ1-38 levels in the CSF of the PS1AD group were significantly lower than those of the three other groups (p < 0.0001, respectively). The levels of Aβ1-40, Aβ1-38 and Aβ1-42 in the CSF of the PS1AD group remained lower than those of the ND group for 4 years. Not only CSF Aβ1-42, but also Aβ1-40 and Aβ1-38 decreased in the advanced stages of PS1AD.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23638752 DOI: 10.3109/13506129.2013.790810
Source DB: PubMed Journal: Amyloid ISSN: 1350-6129 Impact factor: 7.141